EAN 2021

Migraine—new preventive therapies and medication overuse

More Phase 3 clinical trial and real-world data on the efficacy and tolerability of therapies targeting CGRP

Following yesterday’s central focus on new preventive therapies targeting CGRP:

• Further new data on the efficacy and tolerability of these therapies were presented in five 15-minute presentations of clinical trial results by study investigators in the Headache and Pain 2 scientific session
• Two satellite symposia provided in-depth Phase 3 clinical trial and real-world data demonstrating the efficacy and tolerability of anti-calcitonin gene-related peptide (CGRP) monoclonal antibodies (anti-CGRP mAbs)

It is important to address medication overuse when treating migraine

Management of medication overuse also took center stage, not only in the two satellite symposia, but also in a 45-min presentation as part of the 3.5-hour EAN/European Headache Federation (EHF) “Management of migraine” teaching course. This educational session provided a comprehensive overview of the management of migraine and its comorbidities and the many new pharmacologic and non-pharmacologic migraine therapies.

In the Headache and Pain 2 e-poster session, five 2-minute presentations focused on a diverse range of migraine topics.

Further new insights into Alzheimer’s and Parkinson’s diseases

Biomarkers can provide direct evidence for specific AD pathologies

Today’s sessions on Alzheimer's disease started with an EAN/European Union of Geriatric Medicine Society scientific session on emerging and future diagnostics in Alzheimer's disease and dementia. Fascinating insights were provided on new accessible biomarkers and the genetics of dementias, including the role of pre-symptomatic screening.

The Alzheimer’s disease patient journey that started yesterday in a satellite symposium continued today with a focus on patient assessment and diagnosis and will continue tomorrow to discuss management.

Meanwhile, another satellite symposium delved into brain health and the many different risk factors contributing to cognitive decline, highlighting the need for early interventions to prevent progression.

Addressing the risk factors for Alzheimer's disease might prevent progression

Imaging biomarkers for prodromal Parkinson’s diseases were the topic for an early morning Asian Ocean Association of Neurology scientific session. This was followed by a variety of abstract and poster presentations on a variety of Parkinson’s disease-related topics throughout the day, and a satellite symposium on personalizing care for patients with Parkinson’s disease and uncontrolled symptoms.